

Konstantinos Tselios

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8358697/publications.pdf>

Version: 2024-02-01

38
papers

749
citations

516710
16
h-index

552781
26
g-index

40
all docs

40
docs citations

40
times ranked

1263
citing authors

#	ARTICLE	IF	CITATIONS
1	Dyslipidemia in systemic lupus erythematosus: just another comorbidity?. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 604-610.	3.4	79
2	Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. <i>Current Rheumatology Reviews</i> , 2017, 13, 206-218.	0.8	75
3	Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review. <i>Journal of Rheumatology</i> , 2016, 43, 54-65.	2.0	67
4	Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study. <i>Journal of Rheumatology</i> , 2017, 44, 1841-1849.	2.0	49
5	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 1426-1439.	2.0	43
6	Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? A critical appraisal. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 521-525.	3.4	41
7	Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study. <i>Journal of Rheumatology</i> , 2016, 43, 552-558.	2.0	35
8	Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 822-828.	3.4	31
9	Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?. <i>Journal of Rheumatology</i> , 2019, 46, 391-396.	2.0	31
10	Psoriasis in systemic lupus erythematosus: a single-center experience. <i>Clinical Rheumatology</i> , 2017, 36, 879-884.	2.2	26
11	Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 612-617.	0.9	25
12	How can we define low disease activity in systemic lupus erythematosus?. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1035-1040.	3.4	23
13	Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2021, 3, 550-557.	2.1	22
14	Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus. <i>Rheumatology International</i> , 2017, 37, 293-298.	3.0	20
15	Hydroxychloroquine-Induced Cardiomyopathy in Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2016, 22, 287-288.	0.9	18
16	Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?. <i>Journal of Rheumatology</i> , 2019, 46, 64-69.	2.0	18
17	T Regulatory Cells: A Promising New Target in Atherosclerosis. <i>Critical Reviews in Immunology</i> , 2014, 34, 389-397.	0.5	17
18	CD4+CD25highFOXP3+ T regulatory cells as a biomarker of disease activity in systemic lupus erythematosus: a prospective study. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 630-9.	0.8	17

#	ARTICLE	IF	CITATIONS
19	Intracerebral hemorrhage in a patient with SLE and catastrophic antiphospholipid syndrome (CAPS): report of a case. <i>Clinical Rheumatology</i> , 2005, 24, 420-424.	2.2	15
20	Tocilizumab Treatment Leads to a Rapid and Sustained Increase in Treg Cell Levels in Rheumatoid Arthritis Patients: Comment on the Article by Thiolat et al. <i>Arthritis and Rheumatology</i> , 2014, 66, 2638-2638.	5.6	14
21	Increase of peripheral T regulatory cells during remission induction with cyclophosphamide in active systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 790-795.	1.9	12
22	Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study. <i>Arthritis Care and Research</i> , 2016, 68, 1497-1504.	3.4	12
23	Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?. <i>Journal of Rheumatology</i> , 2020, 47, 1366-1373.	2.0	8
24	Antiphospholipid Syndrome in Greece: Clinical and Immunological Study and Review of the Literature. <i>Angiology</i> , 2004, 55, 421-430.	1.8	7
25	Influenza A/H1N1 septic shock in a patient with systemic lupus erythematosus. A case report. <i>BMC Infectious Diseases</i> , 2011, 11, 358.	2.9	6
26	The Role of Anti-Phosphatidylserine/Prothrombin Antibodies in Thrombotic Manifestations of Systemic Lupus Erythematosus Patients. <i>Frontiers in Neurology</i> , 2013, 4, 66.	2.4	6
27	Factors Associated With Rapid Progression to Endstage Kidney Disease in Lupus Nephritis. <i>Journal of Rheumatology</i> , 2021, 48, 228-231.	2.0	6
28	Medium Versus High Initial Prednisone Dose for Remission Induction in Lupus Nephritis: A Propensity Score-Matched Analysis. <i>Arthritis Care and Research</i> , 2022, 74, 1451-1458.	3.4	6
29	Celiac trunk aneurysm in a patient with Adamantiades-Behçet disease. <i>Vascular Medicine</i> , 2014, 19, 77-78.	1.5	4
30	Systemic Sclerosis and Silicone Breast Implant: A Case Report and Review of the Literature. <i>Case Reports in Rheumatology</i> , 2014, 2014, 1-3.	0.6	4
31	Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence. <i>European Journal of Rheumatology</i> , 2020, 7, S110-S116.	0.6	4
32	Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. <i>Rheumatology</i> , 2021, 60, 73-80.	1.9	3
33	Pure red cell aplasia complicating B cell small lymphocytic lymphoma: a case report. <i>International Journal of Hematology</i> , 2008, 88, 341-342.	1.6	2
34	Fatal Refractory Thrombotic Thrombocytopenic Purpura Complicating Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 412-414.	0.9	1
35	T Regulatory Cells in Systemic Lupus Erythematosus: Current Knowledge and Future Prospects. , 2017, , .		1
36	T Regulatory Cells and Helicobacter pylori-Associated Diseases. <i>Immuno-gastroenterology</i> , 2013, 2, 38.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Dr. Tselios, <i>et al</i> reply. Journal of Rheumatology, 2016, 43, 1767-1767.	2.0	0
38	Dr. Tselios, et al, reply. Journal of Rheumatology, 2019, 46, 1422.2-1422.	2.0	0